Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Landi, Daniel ^a,b   Hegde, Meenakshi ^a,b   Ahmed, Nabil ^a,b,c  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b TEXAS CHILDREN S CANCER CENTER   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Adoptive cellular therapy; Cytomegalovirus; Glioblastoma; Immunotherapy

Indexed keywords

B7 ANTIGEN; CD133 ANTIGEN; CD28 ANTIGEN; CD34 ANTIGEN; CD86 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; CYTOMEGALOVIRUS ANTIGEN PP65; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 3; GAMMA INTERFERON; GROWTH DIFFERENTIATION FACTOR 15; HUMAN CYTOMEGALOVIRUS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; NESTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN; TEMOZOLOMIDE; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALGANCICLOVIR; VASCULOTROPIN; VIRUS ANTIGEN; VIRUS DNA;

APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HISTOCOMPATIBILITY; HUMAN; HUMAN CYTOMEGALOVIRUS GENE; HUMAN HERPESVIRUS 8; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; MACROPHAGE; MICROGLIA; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VIRUS GENE;

EID: 84915805617     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00338     Document Type: Review

References (57)

1. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol (2009) 29(1):1-42. doi: 10.1615/CritRevImmunol.v29.i1.10
2. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 12(10):1160-6. doi:10.1038/nm1475
3. Straathof KCM, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood (2005) 105(5):1898-904. doi:10.1182/blood-2004-07-2975
4. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother (2008) 31(5):500-5. doi:10.1097/CJI.0b013e318177092b
5. Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong L-Y, Wu A, et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 17(14):4642-9. doi:10.1158/1078-0432.CCR-11-0414
6. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 62(12):3347-50.
7. Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol (2012) 14(3):246-55. doi:10.1093/neuonc/nor227
8. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol (2008) 116(1):79-86. doi:10.1007/s00401-008-0359-1
9. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet (2002) 360(9345):1557-63. doi:10.1016/S0140-6736(02)11524-8
10. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol (2003) 170(3):998-1002. doi:10.1097/01.ju.0000080263.46164.97
11. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2008) 10(1):10-8. doi:10.1215/15228517-2007-035
12. Lau SK, Chen Y-Y, Chen W-G, Diamond DJ, Mamelak AN, Zaia JA, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol (2004) 18(6):838-43. doi:10.1038/modpathol.3800352
13. Rahbar A, Orrego A, Peredo I, Dzabic M, Wolmer-Solberg N, Strååt K, et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol (2013) 57(1):36-42. doi:10.1016/j.jcv.2012.12.018
14. Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer J (2003) 9(3):157-66. doi:10.1097/00130404-200305000-00004
15. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother (2012) 35(2):159-68. doi:10.1097/CJI.0b013e318247642f
16. Cheung AK, Abendroth A, Cunningham AL, Slobedman B. Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. Blood (2006) 108(12):3691-9. doi:10.1182/blood-2005-12-026682
17. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest (2011) 121(5):1673-80. doi:10.1172/JCI45449
18. Reeves M, Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol (2008) 325:297-313. doi:10.1007/978-3-540-77349-8_17
19. Michaelis M, Doerr HW, Cinatl J Jr. Oncomodulation by human cytomegalovirus: evidence becomes stronger. Med Microbiol Immunol (2009) 198(2):79-81. doi:10.1007/s00430-009-0107-8
20. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res (2011) 157(2):193-203. doi:10.1016/j.virusres.2010.10.026
21. Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, Fraile-Ramos A, et al. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal (2010) 3(133):ra58. doi:10.1126/scisignal.2001180
22. Maussang D, Langemeijer E, Fitzsimons CP, Stigter-van Walsum M, Dijkman R, Borg MK, et al. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res (2009) 69(7):2861-9. doi:10.1158/0008-5472.CAN-08-2487
23. Wu A, Wei J, Kong L-Y, Wang Y, Priebe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 12(11):1113-25. doi:10.1093/neuonc/noq082
24. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A (2000) 97(4):1695-700. doi:10.1073/pnas.97.4.1695
25. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8(6):467-77. doi:10.1038/nri2326
26. Chan G, Bivins-Smith ER, Smith MS, Smith PM, Yurochko AD. Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. J Immunol (2008) 181(1):698-711. doi:10.4049/jimmunol.181.1.698
27. Chan G, Bivins-Smith ER, Smith MS, Yurochko AD. NF-kappaB and phosphatidylinositol 3-kinase activity mediates the HCMV-induced typical M1/M2 polarization of monocytes. Virus Res (2009) 144(1-2):329-33. doi:10.1016/j.virusres.2009.04.026
28. Cobbs CS, Soroceanu L, Denham S, Zhang W, Kraus MH. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res (2008) 68(3):724-30. doi:10.1158/0008-5472.CAN-07-2291
29. Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res (2010) 16(2):461-73. doi:10.1158/1078-0432.CCR-09-1983
30. Sinclair JH, Reeves MB. Human cytomegalovirus manipulation of latently infected cells. Viruses (2013) 5(11):2803-24. doi:10.3390/v5112803
31. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 359(5):539-41. doi:10.1056/NEJMc0804818
32. Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res (2014) 74(13):3466-76. doi:10.1158/0008-5472.CAN-14-0296
33. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol (2012) 90(9):872-80. doi:10.1038/icb.2012.19
34. Hellstrand K, Martner A, Bergström T. Valganciclovir in patients with glioblastoma. N Engl J Med (2013) 369(21):2066-7. doi:10.1056/NEJMc1312413
35. Lúcia M, Crespo E, Melilli E, Cruzado JM, Luque S, Llaudó I, et al. Preformed frequencies of Cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis (2014) 59(11):1537-45. doi:10.1093/cid/ciu589
36. Ahmed N. CMV-specific cytotoxic T lymphocytes expressing CAR targeting HER2 in patients with GBM (HERT-GBM). ClinicalTrialsgov (2014).
37. Sampson J. Evaluation of recovery from drug-induced lymphopenia using cytomegalovirus-specific T-cell adoptive transfer (ERaDICATe). ClinicalTrialsgov (2014).
38. Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 9(1):67-78. doi:10.1158/1535-7163.MCT-09-0734
39. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 5:67. doi:10.1186/1476-4598-5-67
40. Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, Graeber S, et al. Expression pattern of galectin-3 in neural tumor cell lines. J Neurosci Res (2000) 60(1):45-57. doi:10.1002/(SICI)1097-4547(20000401)60:1<45::AID-JNR5>3.0.CO;2-Y
41. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother (1997) 45(2):77-87. doi:10.1007/s002620050405
42. Hegde M, Corder A, Chow KKH, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther (2013) 21(11):2087-101. doi:10.1038/mt.2013.185
43. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 10(A):133-46.
44. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res (2003) 63(21):7462-7.
45. Chow KH, Gottschalk S. Cellular immunotherapy for high-grade glioma. Immunotherapy (2011) 3(3):423-34. doi:10.2217/imt.10.110
46. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 19(12):3165-75. doi:10.1158/1078-0432.CCR-12-3314
47. Miller SD, McMahon EJ, Schreiner B, Bailey SL. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann N Y Acad Sci (2007) 1103:179-91. doi:10.1196/annals.1394.023
48. Daga A, Orengo AM, Gangemi RM, Marubbi D, Perera M, Comes A, et al. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer (2007) 121(8):1756-63. doi:10.1002/ijc.22901
49. Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med (2013) 369(10):985-6. doi:10.1056/NEJMc1302145
50. Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer (2013) 133(5):1204-13. doi:10.1002/ijc.28111
51. Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest (2011) 121(10):4043-55. doi:10.1172/JCI57147
52. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J (1998) 12(12):1063-73.
53. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res (2011) 71(7):2664-74. doi:10.1158/0008-5472.CAN-10-3055
54. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res (2000) 60(5):1306-11.
55. Bollard CM, Rossig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 99(9):3179-87. doi:10.1182/blood. V99.9.3179
56. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-l1 antibody in patients with advanced cancer. N Engl J Med (2012) 366(26):2455-65. doi:10.1056/NEJMoa1200694
57. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366(26):2443-54. doi:10.1056/NEJMoa1200690